Skip to content
‹ Back to IndustriesSciences

Overcoming Problems with Hybrid Rocket Engines is Key to Launching Us Further into Space

Hybrid rocket engines combine elements of both liquid and solid propulsion systems to offer improved efficiency, safety, and control compared to traditional rocket technologies. Advances in hybrid propulsion are seen as a key enabler for more accessible and cost-effective space exploration. Greater accessibility to space could accelerate scientific discovery and technological innovation.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · HybridRobert FabianRocket EnginesSpace
Share

Key takeaways

01

Hybrid rocket engines offer a middle ground between liquid and solid propulsion, providing better control and safety.

02

Improved rocket technology lowers barriers to space exploration for commercial and scientific missions.

03

Ongoing development of hybrid engines could unlock new opportunities for deep space travel and research.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Hybrid isn’t just the word with us earthlings, it’s also the next big thing in space technology. Hybrid rocket engines have been developed to increase efficiency and control over more established liquid and solid rocket engines. With better rocket technology comes more accessible space exploration, meaning the potential for scientific discoveries and technological advancements grows exponentially. In fact, according to a report by Morgan Stanley, the global space industry could be worth $1.1 trillion or more by 2040.

Still, while hybrid rockets offer certain advantages over the more traditional rockets, they also come with several drawbacks, including the fact that refueling hybrid rockets is more challenging than refueling liquid and solid rockets. Large hybrid orbital rockets also require turbopumps, but turbopumps can’t use the same fuel and oxidizer as in liquid-propellant rockets. Finally, there hasn’t been as much research on hybrid rockets as with other rockets, so many of their problems have not been fully addressed.

Private aerospace company Vaya Space has been making waves in the industry with its revolutionary Vortex hybrid engine technology. Robert Fabian, the company’s Chief Operating Officer, offers deeper insights into this new technology and its potential impact on space travel.

Robert’s Thoughts:

“What makes Vaya Space unique really is our engine technology, what we call the Vortex hybrid engine. We’ve taken the historical problems of hybrid engines and core performance and combustion instability and solved them, producing an engine that’s significantly cheaper, significantly simpler, and significantly safer than anything else out there on the market.

When I first heard about this technology, I didn’t believe it. I had to do the math myself to make sure it would work, and I’ve watched it go from math on a page and a concept to lab scale tests, to larger engine tests, to flight tests, and I’m really looking forward to seeing the production engine for our Dauntless launch vehicle fire for the first time.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Lilly breaks ground on a $5B Virginia bioconjugate plant and expects its first building to open in 2030

Lilly breaks ground on a $5B Virginia bioconjugate plant and expects its first building to open in 2030

Eli Lilly held a groundbreaking on Oct. 22 for a $5 billion manufacturing plant in Goochland County, Virginia. The company expects the first building to open in 2030. Lilly has also committed $40 million to the Virginia Center for Advanced Pharmaceutical Manufacturing, a statewide workforce development network that brings together industry, government and higher education partners. The network's plans include a pilot-scale training center in Goochland County, slated to open in 2028. That timing could let workers start training before the plant begins production.

  • 01Goochland’s pilot-scale training center is slated to open in 2028, two years before Lilly expects its first production building in 2030—signaling workforce readiness as the earliest milestone at Lilly’s first dedicated, fully integrated API and drug product facility for its bioconjugate platform and monoclonal antibody portfolio.
  • 02For anyone tracking new ADC supply, Goochland is a later story: Lilly expects to open the first building in 2030 and the second in 2031.

Nov 15, 2026

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Andelyn Biosciences will develop and manufacture CLZ002, Celliaz’s investigational AAV2 gene therapy for retinitis pigmentosa, supporting IND-enabling studies and a planned Phase 1/2 trial. CLZ002 targets a retinal repair mechanism rather than specific mutations. If it works as intended, one manufacturing process could serve patients across many genetic causes of the disease.

  • 01Retinitis pigmentosa can arise from mutations in more than 90 genes; CLZ002 targets a retinal repair mechanism, and if it works as intended one AAV2 manufacturing process could serve patients that gene-specific programs would split into many products.
  • 02For a pre-IND sponsor, putting plasmid and viral vector production with one CDMO can mean fewer handoffs, and the questions worth settling early are who owns the process built on a proprietary platform and how it would move if needed.

Nov 14, 2026

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab hiring budgets for 2027 carry a net outlook of just +2, down from +10, while consumables sit at +30 and raw materials at +31. Labs are paying for supplies and planning capital purchases further ahead. New positions face the toughest scrutiny.

  • 01Labs heading into 2027 expect their reagent budgets to grow and their headcount budgets to stall: consumables carry a net outlook of +30, hiring just +2.
  • 02Lab Manager’s read: if consumables spending stays flat, the lab is probably buying less—because respondents reported rising costs across many supply items, from reagents to shipping.
  • 03Hiring gets treated as a recurring cost, not a one-time purchase; one published example estimates ~$46,000/year for a graduate student and $80,000–$100,000 for a postdoc (with fringe) at one institution. Lab Manager recommends justifying new roles with throughput, turnaround and risk—while separating price from volume in supply-line requests.

Nov 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512